Key result
In three fatal cases of COVID-19, heart rate variability substantially decreased and actual heart rate increases in response to fever were less than expected, preceding increases in cardiac biomarkers.
Why the study?
SARS-CoV-2 binds to ACE2 expressed in the cardiovascular system and can damage the myocardium, prompting evaluation of decreased heart rate variability and cardiac injury.
Case Report (n=3)
No
Decreased heart rate variability and a blunted tachycardic response to fever may serve as early indicators of COVID-19-related cardiac injury, preceding the elevation of traditional myocardial biomarkers.
May warrant cardiac monitoring in COVID-19; hypothesis-generating and requires prospective validation before practice change.
Purpose: Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which primarily infects the lower airways and binds to angiotensin-converting enzyme 2 (ACE2) on alveolar epithelial cells. ACE2 is widely expressed not only in the lungs but also in the cardiovascular system. Therefore, SARS-CoV-2 can also damage the myocardium. This report aimed to highlight decreased heart rate variability (HRV) and cardiac injury caused by SARS-CoV-2. Materials and Methods: We evaluated three COVID-19 patients who died. Patients' data were collected from electronic medical records. We collected patient's information, including baseline information, lab results, body temperature, heart rate (HR), clinical outcome and other related data. We calculated the HRV and the difference between the expected and actual heart rate changes as the body temperature increased. Results: As of March 14, 2020, 3 (2.2%) of 136 patients with COVID-19 in Tianjin died in the early stage of the COVID-19 epidemic. The immediate cause of death for Case 1, Case 2, and Case 3 was cardiogenic shock, cardiac arrest and cardiac arrest, respectively. The HRV were substantially decreased in the whole course of all three cases. The actual increases in heart rate were 5 beats/min, 13 beats/min, and 4 beats/min, respectively, less than expected as their temperature increased. Troponin I and Creatine Kinase MB isoenzyme (CK-MB) were substantially increased only in Case 3, for whom the diagnosis of virus-related cardiac injury could not be made until day 7. In all three cases, decreased in HRV and HR changes occurred earlier than increases in cardiac biomarkers (e.g., troponin I and CK-MB). Conclusions: In conclusion, COVID-19 could affect HRV and counteract tachycardia in response to increases in body temperature. The decreases of HRV and HR changes happened earlier than the increases of myocardial markers (troponin I and CK-MB). It suggested the decreases of HRV and HR changes might help predict cardiac injury earlier than myocardial markers in COVID-19, thus its early identification might help improve patient prognosis. Supplementary Information: The online version contains supplementary material available at 10.1007/s44231-022-00024-1.
No takes yet. Share an insight, caveat, or question.
Yin et al. (2022) conducted a case report in COVID-19 (n=3). SARS-CoV-2 infection was evaluated on Heart rate variability (SDNN) and heart rate changes in response to body temperature increases. In three fatal cases of COVID-19, heart rate variability substantially decreased and actual heart rate increases in response to fever were less than expected, preceding increases in cardiac biomarkers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: